Biofrontera Outlines Ameluz sBCC Launch Timeline and Remediation Goals
During the Q3 2026 earnings call, Biofrontera (BFRI) management provided updated timelines regarding its product pipeline and operational restructuring. CEO Hermann Lubbert indicated that a full commercial launch for Ameluz sBCC is expected in the first quarter of 2027. Additionally, the company aims to have its remediation processes substantially completed by the second quarter of 2027. Management noted significant shifts in their sales capabilities and target markets following two pivotal regulatory or operational events that occurred in September.
Tickers: $BFAGY.CNV
Topics: FDA regulatory updates quarterly earnings revenue drivers